Document
DailyMed Label: Gabazolamine-0.5
Title
DailyMed Label: Gabazolamine
Date
2011
Document type
DailyMed Prescription
Name
Gabazolamine
Generic name
ALPRAZOLAM, CHOLINE
Manufacturer
Physician Therapeutics LLC
Product information
NDC: 68405-024
Product information
NDC: 68405-024
Description
DESCRIPTION
Alprazolam is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.
The chemical name of alprazolam is 8-chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-α] [1,4] benzodiazepine, and its structural formula is:
Alprazolam is a white to off-white crystalline powder, which is soluble in alcohol but which has no appreciable solubility in water at physiological pH.
Each tablet, for oral administration, contains 0.25 mg, 0.5 mg, 1 mg, and 2 mg of alprazolam. The 2 mg tablets are multiscored, and may be divided in half to provide two 1 mg segments, or quarters to provide four 0.5 mg segments.
In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, docusate sodium, lactose (hydrous), magnesium stearate, microcrystalline cellulose, and sodium benzoate. The 0.5 mg tablet also contains FD C yellow #6 aluminum lake (sunset yellow lake). The 1 mg tablet also contains FD C blue #2 aluminum lake. The 2 mg tablet also contains D C yellow #10 aluminum lake.
Alprazolam Structural Formula
Indications
INDICATIONS AND USAGE Alprazolam tablets are indicated for the management of anxiety
disorder (a condition corresponding most closely to the APA Diagnostic and
Statistical Manual (DSM-III-R) diagnosis of generalized anxiety disorder) or the
short-term relief of symptoms of anxiety. Anxiety or tension associated with the
stress of everyday life usually does not require treatment with an
anxiolytic.
Generalized anxiety disorder is characterized by unrealistic or excessive
anxiety and worry (apprehensive expectation) about two or more life
circumstances, for a period of six months or longer, during which the person has
been bothered more days than not by these concerns. At least 6 of the following
18 symptoms are often present in these patients: Motor
Tension (trembling, twitching, or feeling shaky; muscle tension, aches,
or soreness; restlessness; easy fatigability); Autonomic
Hyperactivity (shortness of breath or smothering sensations; palpitations
or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness
or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or
chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge;
exaggerated startle response; difficulty concentrating or ‘mind going blank’
because of anxiety; trouble falling or staying asleep; irritability). These
symptoms must not be secondary to another psychiatric disorder or caused by some
organic factor.
Anxiety associated with depression is responsive to alprazolam.
Alprazolam tablets are also indicated for the treatment of panic disorder,
with or without agoraphobia.
Studies supporting this claim were conducted in patients whose diagnoses
corresponded closely to the DSM-III-R criteria for panic disorder (see CLINICAL STUDIES ).
Panic disorder is an illness characterized by recurrent panic attacks. The
panic attacks, at least initially, are unexpected. Later in the course of this
disturbance certain situations, eg, driving a car or being in a crowded place,
may become associated with having a panic attack. These panic attacks are not
triggered by situations in which the person is the focus of others’ attention
(as in social phobia). The diagnosis requires four such attacks within a four
week period, or one or more attacks followed by at least a month of persistent
fear of having another attack. The panic attacks must be characterized by at
least four of the following symptoms: dyspnea or smothering sensations;
dizziness, unsteady feelings, or faintness; palpitations or tachycardia;
trembling or shaking; sweating; choking; nausea or abdominal distress;
depersonalization or derealization; paresthesias; hot flashes or chills; chest
pain or discomfort; fear of dying; fear of going crazy or of doing something
uncontrolled. At least some of the panic attack symptoms must develop suddenly,
and the panic attack symptoms must not be attributed to some know organic
factors. Panic disorder is frequently associated with some symptoms of
agoraphobia.
Demonstrations of the effectiveness of alprazolam by systematic clinical
study are limited to four months duration for anxiety disorder and four to ten
weeks duration for panic disorder; however, patients with panic disorder have
been treated on an open basis for up to eight months without apparent loss of
benefit. The physician should periodically reassess the usefulness of the drug
for the individual patient.
Dosage
DOSAGE AND ADMINISTRATION Dosage should be individualized for maximum beneficial effect.
While the usual daily dosages given below will meet the needs of most patients,
there will be some who require doses greater than 4 mg/day. In such cases,
dosage should be increased cautiously to avoid adverse effects.
Anxiety Disorders And Transient Symptoms Of Anxiety: Treatment for patients with anxiety should be initiated with a
dose of 0.25 to 0.5 mg given three times daily. The dose may be increased to
achieve a maximum therapeutic effect, at intervals of 3 to 4 days, to a maximum
daily dose of 4 mg, given in divided doses. The lowest possible effective dose
should be employed and the need for continued treatment reassessed frequently.
The risk of dependence may increase with dose and duration of treatment.
In elderly patients, in patients with advanced liver disease or in patients
with debilitating disease, the usual starting dose is 0.25 mg, given two or
three times daily. This may be gradually increased if needed and tolerated. The
elderly may be especially sensitive to the effects of benzodiazepines.
If side effects occur at the recommended starting dose, the dose may be
lowered.
In all patients, dosage should be reduced gradually when discontinuing
therapy or when decreasing the daily dosage. Although there are no
systematically collected data to support a specific discontinuation schedule, it
is suggested that the daily dosage be decreased by no more than 0.5 mg every
three days. Some patients may require an even slower dosage reduction.
Panic Disorder: The successful treatment of many panic disorder patients has
required the use of alprazolam at doses greater than 4 mg daily. In controlled
trials conducted to establish the efficacy of alprazolam in panic disorder,
doses in the range of 1 to 10 mg daily were used. The mean dosage employed was
approximately 5 to 6 mg daily. Among the approximately 1700 patients
participating in the panic disorder development program, about 300 received
alprazolam in dosages of greater than 7 mg/day, including approximately 100
patients who received maximum dosages of greater than 9 mg/day. Occasional
patients required as much as 10 mg a day to achieve a successful response.
Generally, therapy should be initiated at a low dose to minimize the risk of
adverse responses in patients especially sensitive to the drug. Thereafter, the
dose can be increased at intervals equal to at least 5 times the elimination
half-life (about 11 hours in young patients, about 16 hours in elderly
patients). Longer titration intervals should probably be used because the
maximum therapeutic response may not occur until after the plasma levels achieve
steady state. Dose should be advanced until an acceptable therapeutic response
(ie, a substantial reduction in or total elimination of panic attacks) is
achieved, intolerance occurs, or the maximum recommended dose is attained. For
patients receiving doses greater than 4 mg/day, periodic reassessment and
consideration of dosage reduction is advised. In a controlled postmarketing
dose-response study, patients treated with doses of alprazolam greater than 4
mg/day for three months were able to taper to 50% of their total maintenance
dose without apparent loss of clinical benefit.
Because of the danger of withdrawal, abrupt discontinuation of treatment
should be avoided. (See WARNINGS , PRECAUTIONS , DRUG ABUSE AND DEPENDENCE ).
The following regimen is one that follows the principles
outlined above:
Treatment may be initiated with a dose of 0.5 mg three times daily. Depending
on the response, the dose may be increased at intervals of 3 to 4 days in
increments of no more than 1 mg per day. Slower titration to the dose levels
greater than 4 mg/day may be advisable to allow full expression of the
pharmacodynamic effect of alprazolam. To lessen the possibility of interdose
symptoms, the times of administration should be distributed as evenly as
possible throughout the waking hours, that is, on a three or four times per day
schedule.
The necessary duration of treatment for panic disorder patients responding to
alprazolam is unknown. After a period of extended freedom from attacks, a
carefully supervised tapered discontinuation may be attempted, but there is
evidence that this may often be difficult to accomplish without recurrence of
symptoms and/or the manifestation of withdrawal phenomena.
In any case, reduction of dose must be undertaken under close supervision and
must be gradual. If significant withdrawal symptoms develop, the previous dosing
schedule should be reinstituted and, only after stabilization, should a less
rapid schedule of discontinuation be attempted. In a controlled postmarketing
discontinuation study of panic disorder patients which compared this recommended
taper schedule with a slower taper schedule, no difference was observed between
the groups in the proportion of patients who tapered to zero dose; however, the
slower schedule was associated with a reduction in symptoms associated with a
withdrawal syndrome. It is suggested that the dose be reduced by no more than
0.5 mg every three days, with the understanding that some patients may benefit
from an even more gradual discontinuation. Some patients may prove resistant to
all discontinuation regimens.
Contraindications
CONTRAINDICATIONS Alprazolam tablets are contraindicated in patients with known
sensitivity to this drug or other benzodiazepines. Alprazolam may be used in
patients with open angle glaucoma who are receiving appropriate therapy, but is
contraindicated in patients with acute narrow angle glaucoma.
Alprazolam is contraindicated with ketoconazole and intraconazole, since
these medications significantly impair the oxidative metabolism mediated by
cytochrome P450 3A (CYP 3A) (see WARNINGS and PRECAUTIONS-Drug
Interactions ).
Precautions
PRECAUTIONS
General If alprazolam is to be combined with other psychotropic agents or
anticonvulsant drugs, careful consideration should be given to the pharmacology
of the agents to be employed, particularly with compounds which might potentiate
the action of benzodiazepines (see Drug
Interactions ).
As with other psychotropic medications, the usual precautions with respect to
administration of the drug and size of the prescription are indicated for
severely depressed patients or those in whom there is reason to expect concealed
suicidal ideation or plans.
It is recommended that the dosage be limited to the smallest effective dose
to preclude the development of ataxia or oversedation which may be a particular
problem in elderly or debilitated patients. (see DOSAGE AND ADMINISTRATION ). The
usual precautions in treating patients with impaired renal, hepatic or pulmonary
function should be observed. There have been rare reports of death in patients
with severe pulmonary disease shortly after the initiation of treatment with
alprazolam. A decreased systemic alprazolam elimination rate (eg, increased
plasma half-life) has been observed in both alcoholic liver disease patients and
obese patients receiving alprazolam (see CLINICAL PHARMACOLOGY ).
Episodes of hypomania and mania have been reported in association with the
use of alprazolam in patients with depression.
Alprazolam has a weak uricosuric effect. Although other medications with weak
uricosuric effect have been reported to cause acute renal failure, there have
been no reported instances of acute renal failure attributable to therapy with
alprazolam.
Adverse reactions
Side effects to alprazolam, if they occur, are generally observed at the beginning of therapy and usually disappear upon continued medication. In the usual patient, the most frequent side effects are likely to be an extension of the pharmacological activity of alprazolam, eg, drowsiness or light-headedness.
Drug interactions
Drug Interactions The benzodiazepines, including alprazolam, produce additive CNS
depressant effects when coadministered with other psychotropic medications,
anticonvulsants, antihistaminics, ethanol and other drugs which themselves
produce CNS depression.
The steady state plasma concentrations of imipramine and desipramine have
been reported to be increased an average of 31% and 20%, respectively, by the
concomitant administration of alprazolam in doses up to 4 mg/day. The clinical
significance of these changes is unknown.
Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A:
The initial step in alprazolam metabolism is hydroxylation catalyzed by
cytochrome P450 3A (CYP 3A). Drugs which inhibit this metabolic pathway may have
a profound effect on the clearance of alprazolam (see CONTRAINDICATIONS and WARNINGS for additional drugs
of this type.
Drugs Demonstrated To Be CYP 3A Inhibitors Of Possible Clinical Significance
On The Basis Of Clinical Studies Involving Alprazolam (Caution Is Recommended
During Coadministration With Alprazolam:
Fluoxetine --Coadministration of fluoxetine with
alprazolam increased the maximum plasma concentration of alprazolam by 46%,
decreased clearance by 21%, increased half-life by 17%, and decreased measured
psychomotor performance.
Propoxyphene --Coadministration of propoxyphene
decreased the maximum plasma concentration of alprazolam by 6%, decreased
clearance by 38%; and increased half-life by 58%.
Oral contraceptives --Coadministration of oral
contraceptives increased the maximum plasma concentration of alprazolam by 18%,
decreased clearance by 22%, and increased half-life by 29%.
Drugs And Other Substances Demonstrated To Be CYP 3A Inhibitors On The Basis
Of Clinical Studies Involving Benzodiazepines Metabolized Similarly To
Alprazolam Or On The Basis Of In Vitro Studies With
Alprazolam Or Other Benzodiazepines (Caution Is Recommended During
Coadministration With Alprazolam):
Available data from clinical studies of benzodiazepines other than alprazolam
suggest a possible drug interaction with alprazolam for the following:
diltiazem, isoniazid, macrolide antibiotics such as erythromycin and
clarithromycin, and grapefruit juice. Data from in
vitro studies of alprazolam suggest a possible drug interaction with
alprazolam for the following: sertraline and paroxetine. Data from in vitro studies of benzodiazepines other than alprazolam
suggest a possible drug interaction for the following: ergotamine, cyclosporine,
amiodarone, nicardipine, and nifedipine. Caution is recommended during the
coadministration of any of these with alprazolam (see WARNINGS ).
How supplied
HOW SUPPLIED Alprazolam Tablets, USP are supplied as follows:
0.25 mg — Each white, round tablet imprinted with on one side and 027 and bisect on the other contains 0.25 mg of Alprazolam, USP. Tablets are supplied in bottles of 100 (NDC 0228-2027-10), 500 (NDC 0228-2027-50), and 1000 (NDC 0228-2027-96).
0.5 mg — Each peach, round tablet imprinted with on one side and 029 and bisect on the other contains 0.5 mg of Alprazolam, USP. Tablets are supplied in bottles of 100 (NDC 0228-2029-10), 500 (NDC 0228-2029-50), and 1000 (NDC 0228-2029-96).
1 mg — Each blue, round tablet imprinted with on one side and 031 and bisect on the other contains 1 mg of Alprazolam, USP. Tablets are supplied in bottles of 100 (NDC 0228-2031-10), 500 (NDC 0228-2031-50), and 1000 (NDC 0228-2031-96).
2 mg — Each yellow, rectangle shaped, flat faced, beveled edge tablet imprinted with and 039 on one side and multiscored on both sides contains 2 mg of Alprazolam, USP. Tablets are supplied in bottles of 100 (NDC 0228-2039-10), and 500 (NDC 0228-2039-50).
Dispense in tight, light-resistant containers as defined in the USP.
Keep container tightly closed.
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
Clinical pharmacology
CLINICAL PHARMACOLOGY CNS agents of the 1,4 benzodiazepine class presumably exert their
effects by binding at stereo specific receptors at several sites within the
central nervous system. Their exact mechanism of action is unknown. Clinically,
all benzodiazepines cause a dose-related central nervous system depressant
activity varying from mild impairment of task performance to hypnosis.
Following oral administration, alprazolam is readily absorbed. Peak
concentrations in the plasma occur in one to two hours following administration.
Plasma levels are proportionate to the dose given; over the dose range of 0.5 to
3 mg, peak levels of 8.0 to 37 ng/mL were observed. Using a specific assay
methodology, the mean plasma elimination half-life of alprazolam has been found
to be about 11.2 hours (range: 6.3 to 26.9 hours) in healthy adults.
The predominant metabolites are α -hydroxy-alprazolam and a benzophenone
derived from alprazolam. The biological activity of α -hydroxy-alprazolam is
approximately one-half that of alprazolam. The benzophenone metabolite is
essentially inactive. Plasma levels of these metabolites are extremely low, thus
precluding precise pharmacokinetic description. However, their half-lives appear
to be of the same order of magnitude as that of alprazolam. Alprazolam and its
metabolites are excreted primarily in the urine.
The ability of alprazolam to induce human hepatic enzyme systems has not yet
been determined. However, this is not a property of benzodiazepines in general.
Further, alprazolam did not affect the prothrombin or plasma warfarin levels in
male volunteers administered sodium warfarin orally.
In vitro , alprazolam is bound (80 percent) to
human serum protein.
Changes in the absorption, distribution, metabolism and excretion of
benzodiazepines have been reported in a variety of disease states including
alcoholism, impaired hepatic function and impaired renal function. Changes have
also been demonstrated in geriatric patients. A mean half-life of alprazolam of
16.3 hours has been observed in healthy elderly subjects (range: 9.0 to 26.9
hours, n=16) compared to 11.0 hours (range: 6.3 to 15.8 hours, n=16) in healthy
adult subjects. In patients with alcoholic liver disease the half-life of
alprazolam ranged between 5.8 and 65.3 hours (mean: 19.7 hours, n=17) as
compared to between 6.3 and 26.9 hours (mean=11.4 hours, n=17) in healthy
subjects. In an obese group of subjects the half-life of alprazolam ranged
between 9.9 and 40.4 hours (mean=21.8 hours, n=12) as compared to between 6.3
and 15.8 hours (mean=10.6 hours, n=12) in healthy subjects.
Because of its similarity to other benzodiazepines, it is assumed that
alprazolam undergoes transplacental passage and that it is excreted in human
milk.
Clinical studies
CLINICAL EXPERIENCE Patients taking GABAdone have demonstrated significant functional improvements when this therapeutic agent is used for the dietary management of the metabolic processes associated with sleep disorders. The administration of GABAdone results in the induction and maintenance of sleep in patients with sleep disorders. GABAdone has no effect on normal blood pressure.
Package label
1 organization
1 product
Product
ALPRAZOLAM, CHOLINEOrganization
Physician Therapeutics LLC